I. COMMENCED TRADING IN JULY

Company
(Symbol)#

Date
Filed

Date
Comm.

Shares/
Units (M)

Price

Shares
Out
(M)@

Lead, Other
Underwriters

Gross
(M)

Post-
Offering
Market
Cap (M)%

INITIAL OFFERINGS

EvoGenix
Ltd. (Australia;
ASX:EGX)1

7/5/05

7/27/05

36S

A$0.25

128.8

Lodge Corporate Services

A$9
(US$6.85)

A$32.2

OVERALLOTMENTS

Gentium SpA
(Italy; AMEX:GNT)2

1/24/05

7/27/05

0.3S

$9

8.0

Maxim Group I-Bankers Securities (co-lead)

$2.7

$72.0

Total: $9.55M

Number of IPOs in July: 1

Average value of July IPOs: $6.85M

Number of IPOs in 2005: 20

Total raised in IPOs in 2005: $975.41M

Average value of IPOs in 2005: $48.77M

FOLLOW-ON OFFERINGS

Company
(Symbol)#

Date
Filed

Date
Comm.

Shares/
Units (M)

Price

Shares
Out
(M)@

Lead, Other
Underwriters

Gross
(M)

Post-
Offering
Market
Cap (M)%

BioMarin
Pharmaceutical
Inc. (BMRN)3

12/23/02

7/14/05

8.5S

$7.05

73.24

Merrill Lynch & Co.

$59.9

$516.3

Keryx Bio-
pharmaceuticals
Inc. (KERX)4

9/29/04

7/15/05

5.78S

$14.05

37.28

JP Morgan Securities, Bear, Stearns & Co. (co- lead), Jefferies & Co., Oppenheimer & Co., Brean Murray & Co., Punk, Ziegel & Co.

$81.21

$523.8

Momenta
Pharmaceuticals
Inc. (MNTA)5

7/1/05

7/21/05

4.827S

$27.02

30.35

Morgan Stanley & Co, Deutsche Bank Securities (co-lead), Banc of America Securities, SG Cowen & Co

$130.4

$820.1

Rigel
Pharmaceuticals
Inc. (RIGL)6

7/11/05

7/15/05

4.198S

$20.75

24.13

Credit Suisse First Boston, Lehman Brothers (co-lead)

$87.11

$500.7

OVERALLOTMENTS

CV Therapeutics
Inc. (CVTX)7

6/22/05

7/7/05

1.05S

$21.60

44.45

Lehman Brothers, Merrill Lynch & Co. (co-lead), Piper Jaffray & Co., SG Cowen & Co. First Albany Capital

$22.7

$960.1

Total: $381.32M

Number of follow-on offerings in July: 4

Average value of July follow-ons: $89.66M

Number of follow-on offerings in 2005: 26

Total raised in follow-ons in 2005: $1,918.52M

Average value of follow-ons in 2005: $73.79M

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ This column reflects the shares outstanding following the offering, when disclosed.

% Market capitalization is calculated based on the offering price.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange.

Currency conversions are based on exchange rates at the time of the deal.

1. EvoGenix completed an IPO of 36M shares that raised A$9M on the Australian Stock Exchange.

2. Underwriters of Gentium's IPO in June exercised their option on another 300,000 American depository shares, each of which represents one common share. The IPO totaled about 2.7M shares and $24.3M in gross proceeds.

3. BioMarin raised $59.9M in a follow-on offering of 8.5M shares from a shelf registration filed in 2002.

4. Keryx raised $81.21M in a follow-on offering of about 5.78M shares. The totals include the underwriters' purchase of 750,000 shares per their overallotment option.

5. Momenta raised $130.4M in a follow-on offering of 4.827M shares from a shelf registration. Underwriters have an option to purchase up to 724,095 additional shares to cover overallotments.

6. Rigel raised $87.11M in a follow-on offering of about 4.2M shares. The totals include the underwriters' purchase of 547,500 shares per their overallotment option.

7. Underwriters of CV Therapeutics' follow-on offering in June exercised their option on another 1.05M shares. The offering totaled about 8.4M shares and $180.4M in gross proceeds.

II. FILED AND PENDING

Company
(Symbol/
Proposed
Symbol)#*

Date Filed

Shares/
Units
(M)

Price
Range

Shares
Out
(M)@

Lead, Other
Underwriters

Value
(M)

INITIAL OFFERINGS

Accentia Bio-
pharmaceuticals
Inc. (ABPI)1

2/11/05

N/A

N/A

N/A

Jefferies & Co., Robert W. Baird & Co., Ferris, Baker Watts, Stifel, Nicolaus & Co.

$86.25

Advanced Life
Sciences
Holdings Inc.
(ADLS)2

4/28/05

N/A

N/A

N/A

C.E. Unterberg, Towbin, ThinkEquity Partners (co-lead)

$86.25

AlgoRx
Pharmaceuticals
Inc. (AGRX)3

11/29/04

6.8S

$7-$8

N/A

Credit Suisse First Boston, Citigroup (co-lead), Piper Jaffray & Co., Lazard Freres & Co.

$51

Avalon
Pharmaceuticals
Inc. (AVRX)4

5/4/05

N/A

N/A

N/A

Legg Mason Wood Walker, Jefferies & Co.

$57.5

BioNumerik
Pharmaceuticals
Inc. (BNPI)5

6/9/04

N/A

N/A

N/A

UBS Investment Bank, Needham & Co., Leerink Swann & Co., Punk, Ziegel & Co.

$86.25

Celldex
Therapeutics
Inc. (CDEX)6

4/09/04

N/A

N/A

N/A

Janney Montgomery Scott

$50

Coley
Pharmaceutical
Group Inc. (COLY)7

4/20/05

N/A

N/A

N/A

Merrill Lynch & Co., JP Morgan Securities(co-lead), Lazard Freres & Co., Leerink Swann & Co.

$115

CombinatoRx
Inc. (CRXX)8

12/13/04

N/A

N/A

N/A

SG Cowen & Co., Pacific Growth Equities (co-lead), SunTrust Robinson Humphrey, A.G. Edwards

$100

Corus
Pharma Inc.
(CSPH)9

8/27/04

N/A

N/A

N/A

Merrill Lynch & Co., Pacific Growth Equities, SunTrust Robinson Humphrey, JMP Securities

$100

Genomic
Health Inc.
(GHDX)10

7/15/05

N/A

N/A

N/A

JP Morgan Securities, Lehman Brothers (co-lead), Piper Jaffray & Co., Thomas Weisel Partners, JMP Securities

$75

Intarcia
Therapeutics
Inc. (ITCA)11

2/7/05

N/A

N/A

N/A

Credit Suisse First Boston, Pacific Growth Equities, Lazard Freres & Co.

$86.25

Prestwick
Pharmaceuticals
Inc. (PWCK)12

4/22/05

N/A

N/A

N/A

UBS Investment Bank, Deutsche Bank Securities, CIBC World Markets,

$74.75

Reliant
Pharmaceuticals
Inc. (NYSE:RRX)13

5/20/05

N/A

N/A

N/A

Goldman, Sachs & Co., Banc of America Securities, Deutsche Bank Securities, JP Morgan Securities, William Blair & Co., Lazard Capital Markets

$300

Sunesis
Pharmaceuticals
Inc. (SNNS)14

12/23/04

N/A

N/A

N/A

Lehman Brothers, SG Cowen & Co. (co-lead), Needham & Co.

$86.25

Valera
Pharmaceuticals
Inc. (VLRX)15

3/14/05

N/A

N/A

N/A

UBS Investment Bank, Banc of America (co-lead), First Albany Capital, Fortis Securities

$74.75

FOLLOW-ON OFFERINGS

Allos
Therapeutics
Inc. (ALTH)16

3/5/04

N/A

N/A

N/A

N/A

$75

Anadys
Pharmaceuticals
Inc. (ANDS)17

4/22/05

N/A

N/A

N/A

N/A

$75

Antigenics
Inc. (AGEN)18

8/12/04

N/A

N/A

N/A

N/A

$100

Avanir
Pharmaceuticals
Inc. (AMEX:AVN)19

6/20/05

N/A

N/A

N/A

N/A

$100

Biomira Inc.
(Canada; BIOM)20

7/14/04

N/A

N/A

N/A

N/A

$100

CancerVax
Corp. (CNVX)21

11/8/04

N/A

N/A

N/A

N/A

$80

Cytokinetics
Inc. (CYTK)22

6/14/05

N/A

N/A

N/A

N/A

$100

Encysive
Inc. (ENCY)23

6/7/04

N/A

N/A

N/A

N/A

$150

Exelixis
Pharmaceuticals
Inc. (EXEL)24

10/27/04

N/A

N/A

N/A

N/A

$200

Geron Corp.
(GERN)25

5/5/04

N/A

N/A

N/A

N/A

$150

Hollis-Eden
Pharmaceuticals
Inc. (HEPH)26

7/8/05

5S

$7.90

N/A

N/A

$39.5

Immunicon
Corp. (IMMC)27

5/6/05

N/A

N/A

N/A

N/A

$75

Myogen Inc.
(MYOG)28

6/3/05

N/A

N/A

N/A

N/A

$125

Nabi Bio-
pharmaceuticals
(NABI)29

12/7/04

N/A

N/A

N/A

N/A

$175

Point
Therapeutics
Inc. (POTP)30

12/17/04

N/A

N/A

N/A

N/A

$50

RegeneRx Bio-
pharmaceuticals
Inc. (AMEX:RGN)31

6/16/05

N/A

N/A

N/A

N/A

$60

Santarus
Inc. (SNTS)32

5/12/05

N/A

N/A

N/A

N/A

$75

Seattle Genetics
Inc. (SGEN)33

11/23/04

N/A

N/A

N/A

N/A

$75

Sonus
Pharmaceuticals
Inc. (SNUS)34

4/1/05

N/A

N/A

N/A

N/A

$50

Targeted
Genetics
Corp. (TGEN)35

6/17/04

16.3S

$1.51

N/A

N/A

$24.6

United
Therapeutics
Corp. (UTHR)36

2/10/05

5S

$44.57

N/A

N/A

$222.9

V.I.
Technologies
Inc. (VITX)37

5/13/05

N/A

N/A

N/A

N/A

$50

Vion
Pharmaceuticals
Inc. (VION)38

12/14/04

N/A

N/A

N/A

N/A

$75

ZymoGenetics
Inc. (ZGEN)39

6/17/05

6.5S

$19.02

N/A

Merrill Lynch & Co., Pacific Growth Equities, Bear, Stearns & Co., Piper Jaffray & Co.

$123.6

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange; shelf registrations that have been inactive more than 12-14 months may be removed from the listing.

* Stock symbols for companies seeking to complete IPOs are proposed.

@ This column reflects the shares outstanding following the offering, when disclosed.

N/A = Not available, applicable or reported.

AMEX = American Stock Exchange; NYSE = New York Stock Exchange.

1. Accentia filed to raise up to $86.25M in an IPO.

2. Advanced Life Sciences filed to raise up to $86.25M in an IPO.

3. AlgoRx filed to raise up to $75M in an IPO. It reduced the price range in February. The value is based on the midpoint of that price range.

4. Avalon filed to raise up to $57.55M in an IPO.

5. BioNumerik filed to raise up to $86.25M in an IPO.

6. Celldex filed to raise $50M in an IPO. After the sale Medarex Inc. would own about 75% of the company.

7. Coley filed to raise up to $115M in an IPO.

8. CombinatoRx filed to raise up to $100M in an IPO.

9. Corus filed to raise up to $100M in an IPO.

10. Genomic Health filed to raise up to $75M in an IPO.

11. Intarcia filed to raise up to $86.25M in an IPO.

12. Prestwick filed to raise up to $74.75M in an IPO.

13. Reliant filed to raise up to $300M in an IPO. An undisclosed minority portion of the shares would be sold by an existing shareholder.

14. Sunesis filed to raise up to $86.25M in an IPO.

15. Valera filed to raise up to $74.75M in an IPO.

16. Allos filed a shelf registration statement to sell up to $75M of various securities. It placed $52M in convertible stock in March.

17. Anadys filed a shelf registration statement to sell up to $75M of common stock.

18. Antigenics filed a shelf registration statement to sell up to $100M in various securities. It sold $50M in notes in January.

19. Avanir filed a shelf registration statement covering the sale of up to $100M in various securities.

20. Biomira filed a shelf registration statement in both Canada and the U.S. to sell up to $100M of securities. It placed $12.57M in stock in December.

21. CancerVax filed a shelf registration statement to sell up to $80M in common stock.

22. Cytokinetics filed a shelf registration statement covering up to $100M in various securities.

23. Encysive filed a shelf registration statement to sell up to $150M in various securities. It raised $36.5M through the sale of 4.6M shares in September.

24. Exelixis filed a shelf registration statement covering up to $200M in various securities.

25. Geron filed a shelf registration statement covering the sale of up to $150M of various securities. It sold $40M in stock and warrants in November, and $4M more in April.

26. Hollis-Eden filed a shelf registration statement covering 5M shares or other securities. The value is based on the July 7 closing price.

27. Immunicon filed a shelf registration statement covering up to $75M in various securities. It placed $17.9M in stock on June 30.

28. Myogen filed a universal shelf registration statement covering the sale of $125M of various securities.

29. Nabi filed a shelf registration statement to sell up to $175M in various securities.

30. Point Therapeutics filed a shelf registration statement to sell up to $50M of common stock and warrants. It raised $16.43M in March through the sale of 3.65M shares.

31. RegeneRx filed a shelf registration statement covering the sale of up to $60M in common stock and warrants.

32. Santarus filed a shelf registration statement to sell up to $75M in debt or equity securities.

33. Seattle Genetics filed a shelf registration statement to sell up to $75M in stock.

34. Sonus filed a shelf registration statement to sell up to $50M in common stock.

35. Targeted Genetics filed a shelf registration statement to sell up to 16.3M shares. The value is based on the June 17, 2004, closing price. It raised $6M in a private placement in January.

36. United Therapeutics filed a shelf registration statement covering 5M shares. The value is based on the Feb. 10 closing price.

37. V.I. Technologies filed a shelf registration statement covering up to $50M of equity securities.

38. Vion filed a shelf registration statement covering up to $75M of common stock and warrants. It raised $32.5M through the sale of 10M shares on Jan. 26.

39. ZymoGenetics filed a shelf registration statement covering the sale of up to $200M of common stock. It said on July 28 it was offering 6.5M shares. The value is based on the July 27 closing price.